More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue side. Net profit declined Y/Y, as the drug developer racked up higher SG&A expenses due to increased staffing, consultancy and other professional services costs related to the rollout of Korlym.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs